☰

Stephanie A. Parsons, Ph.D. - Publications

Affiliations: 
2004 University of Cincinnati, Cincinnati, OH 
Area:
Molecular Biology
Tree Info Grants Similar researchers PubMed Report error

8 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Patel S, Alvarez-Guaita A, Melvin A, Rimmington D, Dattilo A, Miedzybrodzka EL, Cimino I, Maurin AC, Roberts GP, Meek CL, Virtue S, Sparks LM, Parsons SA, Redman LM, Bray GA, et al. GDF15 Provides an Endocrine Signal of Nutritional Stress in Mice and Humans. Cell Metabolism. PMID 30639358 DOI: 10.1016/J.Cmet.2018.12.016  0.358
2008 Wagner KR, Fleckenstein JL, Amato AA, Barohn RJ, Bushby K, Escolar DM, Flanigan KM, Pestronk A, Tawil R, Wolfe GI, Eagle M, Florence JM, King WM, Pandya S, Straub V, ... ... Parsons SA, et al. A phase I/IItrial of MYO-029 in adult subjects with muscular dystrophy. Annals of Neurology. 63: 561-71. PMID 18335515 DOI: 10.1002/ana.21338  0.343
2007 Parsons SA, Millay DP, Sargent MA, Naya FJ, McNally EM, Sweeney HL, Molkentin JD. Genetic disruption of calcineurin improves skeletal muscle pathology and cardiac disease in a mouse model of limb-girdle muscular dystrophy. The Journal of Biological Chemistry. 282: 10068-78. PMID 17289669 DOI: 10.1074/Jbc.M609368200  0.67
2006 Parsons SA, Millay DP, Sargent MA, McNally EM, Molkentin JD. Age-dependent effect of myostatin blockade on disease severity in a murine model of limb-girdle muscular dystrophy. The American Journal of Pathology. 168: 1975-85. PMID 16723712 DOI: 10.2353/Ajpath.2006.051316  0.627
2004 Parsons SA, Millay DP, Wilkins BJ, Bueno OF, Tsika GL, Neilson JR, Liberatore CM, Yutzey KE, Crabtree GR, Tsika RW, Molkentin JD. Genetic loss of calcineurin blocks mechanical overload-induced skeletal muscle fiber type switching but not hypertrophy. The Journal of Biological Chemistry. 279: 26192-200. PMID 15082723 DOI: 10.1074/Jbc.M313800200  0.684
2004 Wilkins BJ, Dai YS, Bueno OF, Parsons SA, Xu J, Plank DM, Jones F, Kimball TR, Molkentin JD. Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy. Circulation Research. 94: 110-8. PMID 14656927 DOI: 10.1161/01.Res.0000109415.17511.18  0.64
2003 Parsons SA, Wilkins BJ, Bueno OF, Molkentin JD. Altered skeletal muscle phenotypes in calcineurin Aalpha and Abeta gene-targeted mice. Molecular and Cellular Biology. 23: 4331-43. PMID 12773574 DOI: 10.1128/Mcb.23.12.4331-4343.2003  0.666
2003 Braz JC, Bueno OF, Liang Q, Wilkins BJ, Dai YS, Parsons S, Braunwart J, Glascock BJ, Klevitsky R, Kimball TF, Hewett TE, Molkentin JD. Targeted inhibition of p38 MAPK promotes hypertrophic cardiomyopathy through upregulation of calcineurin-NFAT signaling. The Journal of Clinical Investigation. 111: 1475-86. PMID 12750397 DOI: 10.1172/Jci17295  0.655
Show low-probability matches.